Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to "Hold" at Zacks Research

Key Points

• Zacks Research has downgraded Kiniksa Pharmaceuticals International from a "strong-buy" to a "hold" rating.
• Several research firms have changed their ratings, with Wells Fargo raising the price target to $45 and Jefferies to $54, while Wall Street Zen moved to a "buy" rating from a "strong-buy".
• The stock had a slight decline of 0.4% on Monday and has fluctuated between a 52-week low of $17.82 and a high of $39.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was downgraded by stock analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a report issued on Monday,Zacks.com reports.

A number of other research firms have also issued reports on KNSA. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an "overweight" rating in a research note on Thursday, September 25th. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Saturday, September 27th. Finally, TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They set a "buy" rating and a $60.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $44.29.

Kiniksa Pharmaceuticals International Stock Down 0.4%

NASDAQ KNSA opened at $38.12 on Monday. Kiniksa Pharmaceuticals International has a 52-week low of $17.82 and a 52-week high of $39.12. The business's 50-day moving average price is $34.87 and its 200 day moving average price is $28.91. The firm has a market cap of $2.83 billion, a P/E ratio of 953.24 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Michael R. Megna sold 11,000 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $34.84, for a total transaction of $383,240.00. Following the sale, the chief accounting officer owned 38,011 shares of the company's stock, valued at approximately $1,324,303.24. This trade represents a 22.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Malley sold 78,233 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director owned 12,546 shares in the company, valued at approximately $415,147.14. The trade was a 86.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 603,371 shares of company stock worth $20,434,869 over the last quarter. Company insiders own 53.48% of the company's stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently modified their holdings of the business. GAMMA Investing LLC grew its stake in Kiniksa Pharmaceuticals International by 4,003.9% during the 1st quarter. GAMMA Investing LLC now owns 27,496 shares of the company's stock worth $611,000 after buying an additional 26,826 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Kiniksa Pharmaceuticals International by 6.4% during the first quarter. Rhumbline Advisers now owns 62,700 shares of the company's stock worth $1,393,000 after purchasing an additional 3,745 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth about $301,000. Asset Management One Co. Ltd. acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter valued at approximately $41,000. Finally, Wealthquest Corp bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter valued at approximately $42,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.